{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T11:34:41Z","timestamp":1793100881662,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008952","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T00:00:00Z","timestamp":1317772800000}}],"reference-count":220,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008952.pub2","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T12:33:55Z","timestamp":1317213235000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity"],"prefix":"10.1002","volume":"2011","author":[{"given":"Jonathan L","family":"Marks","sequence":"first","affiliation":[{"name":"Southampton General Hospital; Department of Rheumatology; Tremona Road Southampton Hampshire UK SO16 6YD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra N","family":"Colebatch","sequence":"additional","affiliation":[{"name":"Southampton General Hospital; Department of Rheumatology; Tremona Road Southampton; Consultant Rheumatologist Yeovil District Hospital, Somerset Hampshire UK SO16 6YD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology at Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[{"name":"Southampton General Hospital; Department of Rheumatology; Tremona Road Southampton Hampshire UK SO16 6YD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,5]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0001|cit1","first-page":"118","article-title":"Cox-2 inhibitors: Cardiovascular safety under diclofenac and etoricoxib is comparable","volume":"32","author":"Adler","year":"2007","journal-title":"Aktuelle Rheumatologie"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0002|cit2","first-page":"1223","article-title":"Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy","volume":"228","author":"Adlington","year":"2005","journal-title":"New Zealand Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0003|cit3","first-page":"69","article-title":"Randomized comparative study on programmed released ketoprofen vs. piroxicam in the treatment of rheumatoid arthritis","volume":"26","author":"Amante","year":"1988","journal-title":"Phillippine Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0004|cit4","first-page":"86","article-title":"Worldwide clinical experience with piroxicam (Feldene) The management of rheumatic diseases","volume":"10","author":"Ando","year":"1982","journal-title":"Asia Pacific Congress Services"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0005|cit5","first-page":"294","article-title":"A study of repeated administration of fenbufen in patients with chronic rheumatic disorders and renal impairment","volume":"5","author":"Armstrong","year":"1982","journal-title":"European Journal of Rheumatology & Inflammation"},{"issue":"SUPPL 36","key":"10.1002\/14651858.CD008952.pub2-BIB0006|cit6","first-page":"25","article-title":"Therapeutic implications associated with renal studies of nabumetone","volume":"19","author":"Aronoff","year":"1992","journal-title":"Journal of Rheumatology"},{"issue":"SUPPL. A","key":"10.1002\/14651858.CD008952.pub2-BIB0007|cit7","first-page":"44","article-title":"Long-term renal and hepatic tolerability of naproxen: A review of effects in young and elderly patients","volume":"13","author":"Atkinson","year":"1991","journal-title":"Clinical Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD008952.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0755-4982(05)84023-0","article-title":"Selective cyclooxygenase-2 inhibitors. A population-based analysis of use in France over a three-year period and comparison with randomised clinical trials","volume":"34","author":"Auleley","year":"2005","journal-title":"Presse Medicale"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0010|cit10","first-page":"893","article-title":"From clinical trials to the bedside: How can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials","volume":"23","author":"Baldini","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0011|cit11","first-page":"1805","article-title":"Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis","volume":"33","author":"Barkhuizen","year":"2006","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/03009749609097228","article-title":"Review of clinical trials and benefit\/risk ratio of meloxicam","volume":"Supplement 102","author":"Barner","year":"1996","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2008.12.014","article-title":"Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis","volume":"157","author":"Becker","year":"2009","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD008952.pub2-BIB0014|cit14","first-page":"649","article-title":"Efficacy and tolerability of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis: A double-blind comparison with standard naproxen followed by an open-label trial","volume":"12","author":"Bellamy","year":"1992","journal-title":"Current Medical Research and Opinion"},{"issue":"SUPPL. C","key":"10.1002\/14651858.CD008952.pub2-BIB0015|cit15","first-page":"27","article-title":"A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis","volume":"9","author":"Bennett","year":"1986","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","article-title":"Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis","volume":"44","author":"Bernatsky","year":"2005","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF02032096","article-title":"An assessment of tenoxicam, a nonsteroidal anti-inflammatory drug of long half-life, in patients with impaired renal function suffering from osteoarthritis or rheumatoid arthritis","volume":"8","author":"Bird","year":"1989","journal-title":"Clinical Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD008952.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/art.1780381011","article-title":"Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone","volume":"38","author":"Blackburn","year":"1995","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/ard.2005.036269","article-title":"Problem of the atherothrombotic potential of no-steroidal anti-inflammatory drugs","volume":"65","author":"Bolten","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"SUPPL. 4","key":"10.1002\/14651858.CD008952.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1186\/ar1794","article-title":"Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: Achieving a balance","volume":"7","author":"Borer","year":"2005","journal-title":"Arthritis Research and Therapy"},{"issue":"3 A","key":"10.1002\/14651858.CD008952.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0002-9343(86)90124-5","article-title":"Flurbiprofen versus naproxen in the treatment of rheumatoid arthritis","volume":"80","author":"Brown","year":"1986","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0022|cit22","first-page":"459","article-title":"Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states","volume":"6","author":"Bryson","journal-title":"Drugs & Aging"},{"issue":"670","key":"10.1002\/14651858.CD008952.pub2-BIB0023|cit23","first-page":"309","article-title":"A comparison of flurbiprofen with naproxen in ankylosing spondylitis","volume":"92","author":"Burry","journal-title":"New Zealand Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/014107680609900315","article-title":"Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis","volume":"99","author":"Caldwell","year":"2006","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0025|cit25","first-page":"1","article-title":"Safety profile of a sustained release formulation of etodolac in patients with rheumatoid arthritis and osteoarthritis","volume":"10","author":"Calin","year":"1993","journal-title":"Advances in Therapy"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0026|cit26","first-page":"1742","article-title":"Subclinical renal toxicity in rheumatic patients receiving longterm treatment with nonsteroidal antiinflammatory drugs","volume":"21","author":"Calvo-Alen","year":"1994","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ahj.2006.05.024","article-title":"Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis","volume":"152","author":"Cannon","year":"2006","journal-title":"American Heart Journal"},{"issue":"9549","key":"10.1002\/14651858.CD008952.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","article-title":"Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison","volume":"368","author":"Cannon","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1753-5174.2007.00002.x","article-title":"A comparison of cardiovascular biomarkers in patients treated for three months with etoricoxib, celecoxib, ibuprofen, and placebo","volume":"1","author":"Cannon","year":"2008","journal-title":"Archives of Drug Information"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.phymed.2006.01.010","article-title":"A systematic review of randomised clinical trials of Tripterygium wilfordii for rheumatoid arthritis","volume":"13","author":"Canter","year":"2006","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0031|cit31","first-page":"29","article-title":"A 12-week double-blind study of the efficacy, safety and tolerance of pirazolac b.i.d. compared with indomethacin t.i.d. in patients with ankylosing spondylitis","volume":"16","author":"Carcassi","year":"1990","journal-title":"Drugs under Experimenal and Clinical Research"},{"issue":"11","key":"10.1002\/14651858.CD008952.pub2-BIB0032|cit32","first-page":"iii","article-title":"Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: A systematic review and economic evaluation","volume":"12","author":"Chen","year":"2008","journal-title":"Helath Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0033|cit33","first-page":"254","article-title":"Controlled-release ketoprofen in rheumatoid arthritis and osteoarthritis: comparison of two doses in Thailand","volume":"10","author":"Chivabongs","year":"1988","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0034|cit34","first-page":"113","article-title":"Comparison of naproxen and piroxicam in the treatment of rheumatoid arthritis: A double-blind, crossover study","volume":"4","author":"Chlud","year":"1985","journal-title":"Pharmatherapeutica"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0035|cit35","first-page":"46","article-title":"Effect of piroxicam in the treatment of degenerative arthritis The management of rheumatic diseases","volume":"No 10","author":"Cho","year":"1982","journal-title":"Asia Pacific Congress Service"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.amjmed.2003.09.050","article-title":"Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis","volume":"116","author":"Choi","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0037|cit37","first-page":"100","article-title":"The value and results of long-term studies with diclofenac sodium (Voltarol)","volume":"Suppl 2","author":"Ciccolunghi","year":"1979","journal-title":"Rheumatology & Rehabilitation"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2296-3-10","article-title":"A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis","volume":"3","author":"Collantes","year":"2002","journal-title":"BMC Family Practice"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/rheumatology\/kep005","article-title":"Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)","volume":"48","author":"Combe","year":"2009","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0149-2918(04)90007-0","article-title":"Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials","volume":"26","author":"Curtis","year":"2004","journal-title":"Clinical Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD008952.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1185\/030079906X148238","article-title":"Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib","volume":"22","author":"Curtis","year":"2006","journal-title":"Current Medical Research & Opinion"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0042|cit42","first-page":"249","article-title":"The frequency of coronary heart disease and myocardial infarction in rheumatoid arthritis patients","volume":"20","author":"Czaplicki","year":"1978","journal-title":"Cor et Vasa"},{"issue":"11","key":"10.1002\/14651858.CD008952.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1586\/14737175.6.11.1643","article-title":"Minimizing risks of NSAIDs: Cardiovascular, gastrointestinal and renal","volume":"6","author":"Davies","year":"2006","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"6A","key":"10.1002\/14651858.CD008952.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"33D","DOI":"10.1016\/S0002-9149(02)02235-X","article-title":"Relative risk of cardiovascular events in patients with rheumatoid arthritis","volume":"89","author":"DeMaria","year":"2002","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/pds.1348","article-title":"The CADEUS study: methods and logistics.","volume":"16","author":"Depont","year":"2007","journal-title":"Pharmacoepidemiology and Drug Safety."},{"issue":"4 Pt. 2","key":"10.1002\/14651858.CD008952.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/j.1552-4604.1975.tb01461.x","article-title":"Naproxen and aspirin in rheumatoid arthritis: a multicenter double-blind crossover comparison study","volume":"15","author":"Diamond","year":"1975","journal-title":"Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD008952.pub2-BIB0047|cit47","first-page":"443","article-title":"Multicenter double-blind randomized clinical trial of imidazole salicylate versus ibuprofen in patients with rheumatoid arthritis","volume":"25","author":"DiPerri","year":"1987","journal-title":"International Journal of Clinical Pharmacology, Therapy, & Toxicology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008952.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/rheumatology\/35.suppl_1.68","article-title":"Safety of meloxicam: a global analysis of clinical trials","volume":"35","author":"Distel","year":"1996","journal-title":"British Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0049|cit49","first-page":"246","article-title":"Oxycodone, an option in pain management since 1917 (14 hidroxi-7,8- dehydrocodeinone)","volume":"11","author":"Dominguez Castillejos","year":"2004","journal-title":"Medicina Paliativa"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0050|cit50","first-page":"291","article-title":"Double-blind crossover comparison of piroxicam and indomethacin in rheumatoid arthritis","volume":"6","author":"Domljan","year":"1983","journal-title":"European Journal of Rheumatology and Inflammation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD008952.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/BF00290279","article-title":"A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis","volume":"13","author":"Dreiser","year":"1993","journal-title":"Rheumatology International"},{"issue":"SEC. ISS.","key":"10.1002\/14651858.CD008952.pub2-BIB0052|cit52","first-page":"36","article-title":"The treatment of inflammatory and degenerative joint diseases with Piroxicam - a field trial","volume":"130","author":"Eberl","year":"1980","journal-title":"Weiner Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pain.2004.07.004","article-title":"Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials","volume":"111","author":"Edwards","year":"2004","journal-title":"Pain"},{"issue":"7","key":"10.1002\/14651858.CD008952.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/j.1552-4604.1983.tb02739.x","article-title":"Long-term therapy with tolmetin in rheumatoid arthritis","volume":"23","author":"Ehrlich","year":"1983","journal-title":"Journal of Clinical Pharmacology"},{"issue":"9196","key":"10.1002\/14651858.CD008952.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"issue":"SUPPL. 6","key":"10.1002\/14651858.CD008952.pub2-BIB0056|cit56","first-page":"S1","article-title":"Cardiovascular and renal effects of COX-2-specific inhibitors: Emerging pathophysiological and clinical perspectives","volume":"20","author":"Epstein","year":"2002","journal-title":"Journal of Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0002-9343(90)90344-D","article-title":"Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis","volume":"89","author":"Eriksson","year":"1990","journal-title":"American Journal of Medicine"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD008952.pub2-BIB0058|cit58","first-page":"16","article-title":"The effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis","volume":"114","author":"Eriksson","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.amjcard.2009.01.014","article-title":"An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs","volume":"103","author":"Farkouh","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"SUPPL. 3","key":"10.1002\/14651858.CD008952.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03258202","article-title":"250 million patient-days with tenoxicam. Results and perspectives","volume":"2","author":"Fenner","year":"1990","journal-title":"Drug Investigation"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.reuma.2008.12.015","article-title":"Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice","volume":"5","author":"Ferraz-Amaro","year":"2009","journal-title":"Reumatologia Clinica"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-2001-14217","article-title":"Clinical data on the selective cyclooxygenase-2-inhibitor celecoxib","volume":"26","author":"Fisch","year":"2001","journal-title":"Aktuelle Rheumatologie"},{"issue":"22","key":"10.1002\/14651858.CD008952.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/archinte.164.22.2472","article-title":"Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction","volume":"164","author":"Fischer","year":"2004","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/art.1780160507","article-title":"Fenoprofen calcium in rheumatoid arthritis. A controlled double-blind crossover evaluation","volume":"16","author":"Fries","year":"1973","journal-title":"Arthritis & Rheumatism"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD008952.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0049-0172(97)80049-2","article-title":"Meloxicam: selective COX-2 inhibition in clinical practice","volume":"26","author":"Furst","year":"1997","journal-title":"Seminars in Arthritis & Rheumatism"},{"issue":"15","key":"10.1002\/14651858.CD008952.pub2-BIB0066|cit66","first-page":"724","article-title":"Comparable hepatic and renal safety of two daily dosages of paracetamol (3 g and 4 g) in patients with painful chronic rheumatoid diseases","volume":"30","author":"Ganry","year":"2001","journal-title":"Presse Medicale"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003831","article-title":"Celecoxib for rheumatoid arthritis","author":"Garner","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Supplement","key":"10.1002\/14651858.CD008952.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/03009749209095097","article-title":"Overall safety of Arthrotec","volume":"96","author":"Geis","year":"1992","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD008952.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1368-5031.2004.00398.x","article-title":"Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis","volume":"58","author":"Geusens","year":"2004","journal-title":"International Journal of Clinical Practice"},{"issue":"SUPPL 1.","key":"10.1002\/14651858.CD008952.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/rheumatology\/35.suppl_1.51","article-title":"Tolerability of multiple administration of intramuscular meloxicam: A comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis","volume":"35","author":"Ghozlan","year":"1996","journal-title":"British Journal of Rheumatology"},{"issue":"7134","key":"10.1002\/14651858.CD008952.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/bmj.316.7134.811","article-title":"Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis","volume":"316","author":"Gotzsche","year":"1998","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1185\/03007998509109614","article-title":"Controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis","volume":"9","author":"Grace","year":"1985","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0073|cit73","first-page":"395","article-title":"The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk","volume":"27","author":"Greenberg","year":"2009","journal-title":"Clinical & Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/rheumatology\/XVIII.suppl.112","article-title":"Long-term studies on therapy and tolerance of ketoprofen","volume":"Suppl","author":"Gross","year":"1979","journal-title":"Rheumatology & Rehabilitation"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0075|cit75","first-page":"429","article-title":"Nonsteroidal anti-inflammatory agents--choice between disturbances of gastrointestinal tract and cardiovascular toxicity","volume":"42","author":"Gumbrevicius","year":"2006","journal-title":"Medicina"},{"issue":"7","key":"10.1002\/14651858.CD008952.pub2-BIB0076|cit76","first-page":"691","article-title":"Piroxicam beta-cyclodextrin tablets in articular and extra-articular traumatic injuries, non-chronic painful pathologies of spine and varied rheumatic conditions associated with pain\/inflammation. Multicentric study","volume":"53","author":"Hacbarth","year":"1996","journal-title":"Revista Brasileira de Medicina"},{"issue":"7","key":"10.1002\/14651858.CD008952.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jat.1342","article-title":"Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam","volume":"28","author":"Harirforoosh","year":"2008","journal-title":"Journal of Applied Toxicology"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0149-2918(03)90017-8","article-title":"The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care","volume":"25","author":"Harley","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"20","key":"10.1002\/14651858.CD008952.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2165\/00003495-200464200-00004","article-title":"Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis","volume":"64","author":"Hedner","year":"2004","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2165\/00002018-199512020-00004","article-title":"Tenoxicam and renal function","volume":"12","author":"Heintz","year":"1995","journal-title":"Drug Safety"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/07853890601073445","article-title":"Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs","volume":"39","author":"Hermann","year":"2007","journal-title":"Annals of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1742-7843.2006.pto_302.x","article-title":"Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction","volume":"98","author":"Hernandez-Diaz","year":"2006","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"issue":"11 SUPPL. 1","key":"10.1002\/14651858.CD008952.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.clinthera.2007.12.003","article-title":"Adverse drug interactions involving common prescription and over-the-counter analgesic agents","volume":"29","author":"Hersh","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1185\/030079908X261177","article-title":"The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006","volume":"24","author":"Hochberg","year":"2008","journal-title":"Current Medical Research & Opinion"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/030006057900700111","article-title":"A multicentre double-blind comparison of oxaprozin aspirin therapy on rheumatoid arthritis","volume":"7","author":"Hubsher","year":"1979","journal-title":"Journal of International Medical Research"},{"issue":"12","key":"10.1002\/14651858.CD008952.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1185\/030079907X242575","article-title":"Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK","volume":"23","author":"Jansen","year":"2007","journal-title":"Current Medical Research Opinion"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","article-title":"Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study","volume":"165","author":"Johnsen","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1345\/aph.1C277","article-title":"Effect of cyclooxygenase-2 inhibitors on blood pressure","volume":"37","author":"Johnson","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.amjmed.2008.01.045","article-title":"Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs","volume":"121","author":"Jones","year":"2008","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1213\/01.ane.0000286229.05723.50","article-title":"Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs","volume":"105","author":"Joshi","year":"2007","journal-title":"Anesthesia and Analgesia"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.jhh.1001777","article-title":"Cardiovascular risk and COX-2 inhibition in rheumatological practice","volume":"19","author":"Justice","year":"2005","journal-title":"Journal of Human Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD008952.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s10067-007-0625-y","article-title":"Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: Follow-up of a population-based study","volume":"26","author":"Karstila","year":"2007","journal-title":"Clinical Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00002018-200528090-00005","article-title":"A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data","volume":"28","author":"Kasliwal","year":"2005","journal-title":"Drug Safety"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002281-200201000-00012","article-title":"Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases","volume":"14","author":"Katz","year":"2002","journal-title":"Current Opinion in Rheumatology"},{"issue":"2 SUPPL. 1","key":"10.1002\/14651858.CD008952.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0049-0172(85)80016-0","article-title":"Diclofenac in the treatment of ankylosing spondylitis: Review of worldwide clinical experience and report of a double-blind comparison with indomethacin","volume":"15","author":"Khan","year":"1985","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.58.4.257","article-title":"Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis","volume":"58","author":"Knijff-Dutmer","year":"1999","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0097|cit97","first-page":"1210","article-title":"Short-term treatment of rheumatoid arthritis with parenteral dexindoprofen. A multicentre double blind controlled study with indomethacin","volume":"36","author":"Kolarz","year":"1984","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00290375","article-title":"The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis","volume":"15","author":"Kornasoff","year":"1996","journal-title":"Rheumatology International"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.60.4.327","article-title":"A prospective study of renal disease in patients with early rheumatoid arthritis","volume":"60","author":"Koseki","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/ard.2007.082388","article-title":"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)","volume":"67","author":"Krueger","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14779072.2.2.265","article-title":"Cardiovascular effects of selective cyclooxygenase-2 inhibitors","volume":"2","author":"Krum","year":"2004","journal-title":"Expert Reivew of Cardiovascular Therapy"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/eurjhf\/hfp054","article-title":"Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program","volume":"11","author":"Krum","year":"2009","journal-title":"European Journal of Heart Failure"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/HJH.0b013e328325d831","article-title":"Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study","volume":"27","author":"Krum","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2125.2009.03588.x","article-title":"Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users","volume":"69","author":"Laharie","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0105|cit105","first-page":"366","article-title":"Kidney function in therapy with non-steroidal antiphlogistic drugs. A double-blind cross-over study with diclofenac, indomethacin and piroxicam","volume":"50","author":"Lang","year":"1991","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0106|cit106","first-page":"17","article-title":"Piroxicam versus naproxen in rheumatoid arthritis: A double-blind, cross-over study","volume":"5","author":"Larsen","year":"1985","journal-title":"International Journal of Clinical Pharmacology Research"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/ard.25.5.441","article-title":"Renal disease and drug therapy in rheumatoid arthritis","volume":"25","author":"Lawson","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0025-6196(25)38129-2","article-title":"Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study","volume":"53","author":"Linos","year":"1978","journal-title":"Mayo Clinic Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF02668031","article-title":"Clinical update of the relative safety of nabumetone in long-term clinical trials","volume":"3","author":"Lipani","year":"1995","journal-title":"Inflammopharmacology"},{"issue":"3 A","key":"10.1002\/14651858.CD008952.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9343(86)90107-5","article-title":"Safety of flurbiprofen in the treatment of ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. A summary of liver and kidney assay data","volume":"8-","author":"Lomen","year":"1986","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0111|cit111","first-page":"279","article-title":"Long-term treatment of rheumatoid arthritis with fenclofenac or gold: A controlled, single blind trial comparing clinical and biochemical parameters","volume":"6","author":"Lund","year":"1983","journal-title":"European Journal of Rheumatology and Inflammation"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.11121","article-title":"The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis","volume":"49","author":"Maetzel","year":"2003","journal-title":"Arthritis Care and Research"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0113|cit113","first-page":"259","article-title":"Effects of suprofen on renal function in patients with rheumatoid arthritis","volume":"7","author":"Malandrino","year":"1987","journal-title":"International Journal of Clinical Pharmacology Research"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0114|cit114","first-page":"6","article-title":"COX-2 inhibitors: a CLASS act or Just VIGORously promoted","volume":"6","author":"Malhotra","year":"2004","journal-title":"Medscape General Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1345\/aph.1E543","article-title":"Etoricoxib: A highly selective COX-2 inhibitor","volume":"39","author":"Martina","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"issue":"Suppl A","key":"10.1002\/14651858.CD008952.pub2-BIB0116|cit116","first-page":"1","article-title":"Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review","volume":"46","author":"Mateos","year":"2010","journal-title":"Drugs of Today"},{"issue":"8","key":"10.1002\/14651858.CD008952.pub2-BIB0117|cit117","first-page":"1623","article-title":"A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis","volume":"29","author":"Matsumoto","year":"2002","journal-title":"Journal of Rheumatology"},{"issue":"7 A","key":"10.1002\/14651858.CD008952.pub2-BIB0118|cit118","first-page":"S631","article-title":"Topical use of nitrates, capsacin and tricyclic antidepressants for pain management","volume":"3","author":"McCleane","year":"2003","journal-title":"Advanced Studies in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1009704614147","article-title":"Managing heart failure in the patient with chronic joint disease","volume":"2","author":"McEntegart","year":"1998","journal-title":"Heart Failure Reviews"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0120|cit120","first-page":"679","article-title":"A double-blind multicenter study of sulindac once daily versus sulindac twice daily in rheumatoid arthritis","volume":"41","author":"McIlwain","year":"1987","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/1381612043453153","article-title":"Cardiovascular and renovascular implications of COX-2 inhibition","volume":"10","author":"Meagher","year":"2004","journal-title":"Current Pharmaceutical Design"},{"issue":"7","key":"10.1002\/14651858.CD008952.pub2-BIB0122|cit122","first-page":"603 + 641-2","article-title":"Oxaprozin: A once-daily nonsteroidal anti-inflammatory","volume":"11","author":"Miller","year":"1992","journal-title":"Clinical Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","article-title":"Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports","volume":"7","author":"Moore","year":"2005","journal-title":"Arthritis Research & Therapy"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar2422","article-title":"Discontinuation rates in clinical trials in musculoskeletal pain: Meta-analysis from etoricoxib clinical trial reports","volume":"10","author":"Moore","year":"2008","journal-title":"Arthritis Research and Therapy"},{"issue":"10","key":"10.1002\/14651858.CD008952.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1185\/030079907X219553","article-title":"Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension","volume":"23","author":"Morrison","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"7","key":"10.1002\/14651858.CD008952.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00002018-200629070-00007","article-title":"Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk","volume":"29","author":"Motsko","year":"2006","journal-title":"Drugs Safety"},{"issue":"SUPPL.","key":"10.1002\/14651858.CD008952.pub2-BIB0127|cit127","first-page":"21","article-title":"A long-term study of benorylate in patients with rheumatoid arthritis","volume":"13","author":"Muller-Fassbender","year":"1975","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD008952.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/art.23935","article-title":"Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study","volume":"59","author":"Nadareishvili","year":"2008","journal-title":"Arthritis Care and Research"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Research & Therapy"},{"issue":"3-4","key":"10.1002\/14651858.CD008952.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10354-007-0495-6","article-title":"NIMRA-survey: NSAIDs impact on mortality. Results of an Austrian Survey in 2006","volume":"158","author":"Neumann","year":"2008","journal-title":"Wiener Medizinische Wochenschrift"},{"issue":"SUPPL.","key":"10.1002\/14651858.CD008952.pub2-BIB0131|cit131","first-page":"17","article-title":"Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis","volume":"47","author":"Neustadt","year":"1997","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD008952.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2165\/00003495-200262110-00003","article-title":"Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis","volume":"62","author":"Nurmohamed","year":"2002","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3121\/cmr.2007.698","article-title":"An evidence-based update on nonsteroidal anti-inflammatory drugs","volume":"5","author":"Ong","year":"2007","journal-title":"Clinical Medicine and Research"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ard.44.3.212-b","article-title":"Non-steroidal anti-inflammatory drugs and adverse renal effects","volume":"44","author":"Pal","year":"1985","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0135|cit135","first-page":"1045","article-title":"A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy","volume":"51","author":"Pathan","year":"2003","journal-title":"Journal of the Association of Physicians of India"},{"issue":"8","key":"10.1002\/14651858.CD008952.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/rheumatology\/ken110","article-title":"Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies","volume":"47","author":"Perrot","year":"2008","journal-title":"Rheumatology"},{"issue":"SPEC. ISS. 1","key":"10.1002\/14651858.CD008952.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1055\/s-2008-1052329","article-title":"Review of clinical trial experience with piroxicam","volume":"5","author":"Pitts","year":"1980","journal-title":"Aktuelle Rheumatologie"},{"issue":"4 Suppl 55","key":"10.1002\/14651858.CD008952.pub2-BIB0138|cit138","first-page":"S148","article-title":"A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs","volume":"27","author":"Poddubnyy","year":"2009","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/rheumatology\/kel428","article-title":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: Does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study","volume":"46","author":"Rahme","year":"2007","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0140|cit140","first-page":"379","article-title":"Analgesic effect of acemetacin in rheumatic disease","volume":"35","author":"Rechziegler","year":"1985","journal-title":"Therapiewoche"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008952.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/rheumatology\/35.suppl_1.17","article-title":"A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis","volume":"35","author":"Reginster","year":"1996","journal-title":"British Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1753-5174.2009.00019.x","article-title":"Drugs used in the treatment of rheumatoid arthritis: Relationship between current use and cardiovascular risk factors","volume":"2","author":"Rho","year":"2009","journal-title":"Archives of Drug Information"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.phrs.2009.03.021","article-title":"Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials","volume":"60","author":"Richy","year":"2009","journal-title":"Pharmacological Research"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD008952.pub2-BIB0144|cit144","first-page":"63","article-title":"Long-term double-blind comparison of fenbufen with aspirin in the treatment of rheumatoid arthritis","volume":"25","author":"Roth","year":"1982","journal-title":"Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD008952.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjmed.2005.10.056","article-title":"Meta-Analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs","volume":"119","author":"Salpeter","year":"2006","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0146|cit146","first-page":"50","article-title":"Adverse events with droxicam in thc early clinical trials","volume":"11","author":"Sanchez","year":"1991","journal-title":"European Journal of Rheumatology and Inflammation"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0147|cit147","first-page":"1","article-title":"Etodolac: Safety profile in 992 patients","volume":"2","author":"Sanda","year":"1985","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0148|cit148","first-page":"56","article-title":"An updated safety profile of etodolac in several thousand patients","volume":"10","author":"Schattenkirchner","year":"1990","journal-title":"European Journal of Rheumatology and Inflammation"},{"issue":"11","key":"10.1002\/14651858.CD008952.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/art.22219","article-title":"Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis","volume":"54","author":"Schneeweiss","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/030079904X20231","article-title":"Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: Results of three dose-response studies","volume":"21","author":"Schnitzer","year":"2005","journal-title":"Current Medical Research and Opinion"},{"issue":"10","key":"10.1002\/14651858.CD008952.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/ard.2006.068650","article-title":"Non-steroidal anti-inflammatory drugs and myocardial infarctions: Comparative systematic review of evidence from observational studies and randomised controlled trials","volume":"66","author":"Scott","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/j.1552-4604.1986.tb03522.x","article-title":"The effect of etodolac administration on renal function in patients with arthritis","volume":"26","author":"Shand","year":"1986","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0153|cit153","first-page":"89","article-title":"Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis : a six-month randomised study","volume":"2","author":"Shi","journal-title":"2004"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjmed.2004.03.012","article-title":"Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam","volume":"117","author":"Singh","year":"2004","journal-title":"American Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008952.pub2-BIB0156|cit156","first-page":"359","article-title":"The effect of tiaprofenic acid (Surgam) on blood pressure in treated hypertensive patients","volume":"3","author":"Smith","journal-title":"Australian & New Zealand Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD008952.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1002\/art.20636","article-title":"Cardiovascular risk factors in women with and without rheumatoid arthritis","volume":"50","author":"Solomon","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/art.20418","article-title":"Cardiovascular care and cancer screening in female nurses with and without rheumatoid arthritis","volume":"51","author":"Solomon","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD008952.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/ard.2005.050377","article-title":"Patterns of cardiovascular risk in rheumatoid arthritis","volume":"65","author":"Solomon","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD008952.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.23911","article-title":"Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient group","volume":"59","author":"Solomon","year":"2008","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.pap.0000249930.01907.db","article-title":"Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs","volume":"14","author":"Spalding","year":"2007","journal-title":"American Journal of Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008952.pub2-BIB0163|cit163","first-page":"46","article-title":"Study of repeated administration of fenbufen in patients with chronic rheumatic disorders and renal impairment","volume":"25","author":"Spector","year":"1982","journal-title":"Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0164|cit164","first-page":"29","article-title":"Meloxicam","volume":"19","author":"Sternon","year":"1998","journal-title":"Revue Medicale de Bruxelles"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/art.22094","article-title":"Antirheumatic drug use and the risk of acute myocardial infarction","volume":"55","author":"Suissa","year":"2006","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0166|cit166","first-page":"779","article-title":"The renal excretion of prostaglandins and changes in plasma renin during treatment with either sulindac or naproxen in patients with rheumatoid arthritis and thiazide treated heart failure","volume":"11","author":"Svendsen","year":"1984","journal-title":"Journal of Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/art.24014","article-title":"Subclinical carotid atherosclerosis in patients with psoriatic arthritis","volume":"59","author":"Tam","year":"2008","journal-title":"Arthritis Care and Research"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00003495-198632040-00001","article-title":"Oxaprozin: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy","volume":"32","author":"Todd","year":"1986","journal-title":"Drugs"},{"issue":"SUPPL. C","key":"10.1002\/14651858.CD008952.pub2-BIB0169|cit169","first-page":"37","article-title":"Comparison of diflunisal and aspirin in long-term treatment of patients with rheumatoid arthritis","volume":"9","author":"Turner","year":"1986","journal-title":"Clinical Therapeutics"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD008952.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0049-0172(88)90042-X","article-title":"Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis","volume":"17","author":"Turner","year":"1988","journal-title":"Seminars in Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard.46.3.233","article-title":"Renal impairment associated with non-steroidal anti-inflammatory drugs","volume":"46","author":"Unsworth","year":"1987","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study","volume":"52","author":"Heijde","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/ard.2007.087254","article-title":"The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs","volume":"68","author":"Linden","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD008952.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2796.2008.01991.x","article-title":"Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?","volume":"264","author":"Staa","year":"2008","journal-title":"Journal of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1345\/aph.1A212","article-title":"Adverse drug events involving COX-2 inhibitors","volume":"37","author":"Verrico","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD008952.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.162.10.1105","article-title":"Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis","volume":"162","author":"Watson","year":"2002","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00045391-200007030-00004","article-title":"Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor","volume":"7","author":"Whelton","year":"(2000)","journal-title":"American Journal of Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD008952.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.ki.5001766","article-title":"Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen","volume":"70","author":"Whelton","year":"2006","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","article-title":"Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac","volume":"89","author":"White","year":"2002","journal-title":"The American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008952.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjcard.2006.07.069","article-title":"Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials","volume":"99","author":"White","year":"2007","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0182|cit182","first-page":"22","article-title":"A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis","volume":"Suppl 1","author":"Wojtulewski","journal-title":"1996"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0183|cit183","first-page":"1143","article-title":"Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary care","volume":"31","author":"Wolfe","year":"2004","journal-title":"Journal of Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD008952.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.23811","article-title":"The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis","volume":"58","author":"Wolfe","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0185|cit185","unstructured":"Wong M Effects of indomethacin and rofecoxib on vascular function in rheumatoid arthritis Internal Medicine Journal 2006"},{"issue":"12","key":"10.1002\/14651858.CD008952.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1055\/s-2008-1081346","article-title":"Sinomenine versus NSAIDs for the treatment of rheumatoid arthritis: A systematic review and meta-analysis","volume":"74","author":"Xu","year":"2008","journal-title":"Planta Medica"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00124743-200212000-00005","article-title":"Prescription and tolerability of meloxicam in day-to-day practice: Postmarketing observational cohort study of 13,307 patients in germany","volume":"8","author":"Zeidler","year":"2002","journal-title":"Journal of Clinical Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD008952.pub2-BIB0188|cit188","first-page":"855","article-title":"A multicenter study of the efficacy and tolerability of aceclofenac in the treatment of rheumatoid disease (arthritis)","volume":"54","author":"Zerbini","year":"1997","journal-title":"Revista Brasileira de Medicina"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD008952.pub2-BIB0189|cit189","first-page":"S392","article-title":"Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice","volume":"8","author":"Zhao","year":"2002","journal-title":"American Journal of Managed Care"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00000441-195823640-00007","article-title":"Phenylbutazone therapy in patients with rheumatic disease and coincidental essential hypertension","volume":"236","author":"Zuckner","year":"1958","journal-title":"American Journal of the Medical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0192|cit192","article-title":"British National Formulary","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2010"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008952.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1002\/art.21288","article-title":"Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors","volume":"52","author":"Chung","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"R186","DOI":"10.1186\/ar2098","article-title":"Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis","volume":"8","author":"Chung","year":"2006","journal-title":"Arthritis Research and Therapy"},{"issue":"6","key":"10.1002\/14651858.CD008952.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1345\/aph.1L031","article-title":"Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy","volume":"42","author":"Colucci","year":"2008","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0197|cit197","article-title":"Study quality assessment","volume-title":"Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. Report 4","author":"Khan","year":"March 2001"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMe048225","article-title":"Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors","volume":"351","author":"Angelis","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008952.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2125.2008.03196.x","article-title":"Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report","volume":"66","author":"Smedt","year":"August 2008","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0200|cit200","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch9"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0201|cit201","unstructured":"EPOC data collection checklist URL: http:\/\/epoc.cochrane.org\/epoc-resources-review-authors"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archinte.162.3.265","article-title":"Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam study","volume":"162","author":"Feenstra","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jpain.2008.09.012","article-title":"Patient barriers to pain management may contribute to poor pain control in rheumatoid arthritis","volume":"10","author":"Fitzcharles","year":"2009","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcomes in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0205|cit205","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0206|cit206","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/ar2069","article-title":"Arthritis and pain: Neurogenic origin of joint pain","volume":"8","author":"McDougall","year":"2006","journal-title":"Arthritis Research and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD008952.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardfail.2006.11.006","article-title":"Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain","volume":"13","author":"Murphy","year":"2007","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archinte.162.10.1111","article-title":"Association between naproxen use and protection against acute myocardial infarction","volume":"162","author":"Rahme","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0212|cit212","first-page":"155","article-title":"Cardiovascular risk of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease","volume":"2","author":"Ray","year":"2009","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0213|cit213","unstructured":"Reeves BC Deeks JJ Higgins JPT Wells GA (editors) Chapter 13: Including non-randomized studies In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org"},{"issue":"24","key":"10.1002\/14651858.CD008952.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \"high-grade\" systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0215|cit215","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch11"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0216|cit216","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch12"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0217|cit217","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD008952.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1177\/147323001003800402","article-title":"Patient perceptions concerning pain management in the treatment of rheumatoid arthritis","volume":"38","author":"Taylor","year":"2010","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs; network meta-analysis.","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008952.pub2-BIB0220|cit220","unstructured":"Wells GA Shea B O'Connell D Peterson J Welch V Losos M Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa, Canada URL: http:\/\/www.lri.ca\/programs\/ceu\/oxford.htm"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008952.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T11:03:49Z","timestamp":1793099029000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008952.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,10,5]]},"references-count":220,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008952.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,5]]}}}